Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...